The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Do patients enrolled in clinical trials really represent the acute myeloid leukemia population?
Mycal Casey
December 17, 2021
During the 63rd ASH Annual Meeting and Exposition, Know AML spoke with Mycal Casey, Augusta University, Augusta, US. We asked, Do patients enrolled in clinical trials really represent the acute myeloid leukemia population?
Casey begins by discussing underrepresentation of Hispanic and African American populations as well as women in clinical trials. He goes on to outline the impact of mortality on clinical trials that lead to drug approval and global disparities in trial populations. Finally, Casey makes 3 suggestions that could improve the applicability of data and representation in clinical trials.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
